Literature DB >> 33988225

Fecal Diversion for Perianal Crohn Disease in the Era of Biologic Therapies: A Multicenter Study.

Jeffrey D McCurdy1,2, Jacqueline Reid3, Russell Yanofsky4, Vigigah Sinnathamby1, Edgar Medawar4, Lara Williams5, Talat Bessissow4, Greg Rosenfeld3.   

Abstract

BACKGROUND: The natural history of perianal Crohn disease (PCD) after fecal diversion in the era of biologics is poorly understood. We assessed clinical and surgical outcomes after fecal diversion for medically refractory PCD and determined the impact of biologics.
METHODS: We performed a retrospective, multicenter study from 1999 to 2020. Patients who underwent fecal diversion for refractory PCD were stratified by diversion type (ostomy with or without proctectomy). Times to clinical and surgical outcomes were estimated using Kaplan-Meier methods, and the association with biologics was assessed using multivariable Cox proportional hazards models.
RESULTS: Eighty-two patients, from 3 academic institutions, underwent a total of 97 fecal diversions: 68 diversions without proctectomy and 29 diversions with proctectomy. Perianal healing occurred more commonly after diversion with proctectomy than after diversion without proctectomy (83% vs 53%; P = 0.021). Among the patients who had 68 diversions without proctectomy, with a median follow-up of 4.9 years post-diversion (interquartile range, 1.66-10.19), 37% had sustained healing, 31% underwent surgery to restore bowel continuity, and 22% underwent proctectomy. Ostomy-free survival occurred in 21% of patients. Biologics were independently associated with avoidance of proctectomy (hazard ratio, 0.32; 95% confidence interval, 0.11-0.98) and surgery to restore bowel continuity (hazard ratio, 3.10; 95% confidence interval, 1.02-9.37), but not fistula healing.
CONCLUSIONS: In this multicenter study, biologics were associated with bowel restoration and avoidance of proctectomy after fecal diversion without proctectomy for PCD; however, a minority of patients achieved sustained fistula healing after initial fecal diversion or after bowel restoration. These results highlight the refractory nature of PCD.
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  biologics; fecal diversion; perianal disease; proctectomy

Mesh:

Year:  2022        PMID: 33988225     DOI: 10.1093/ibd/izab086

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  3 in total

1.  Mesenchymal Stem/Stromal Cell Therapy Is More Cost-Effective Than Fecal Diversion for Treatment of Perianal Crohn's Disease Fistulas.

Authors:  Sheeva Johnson; Jeffrey S Hoch; Wissam J Halabi; Jeffrey Ko; Jan Nolta; Maneesh Dave
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

2.  Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.

Authors:  Lester Tsai; Jeffrey D McCurdy; Christopher Ma; Vipul Jairath; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2022-10-03       Impact factor: 7.290

Review 3.  Managing complex perianal disease after anti-TNF failure: Where to go next?

Authors:  Clare Yzet; Franck Brazier; Charles Sabbagh; Mathurin Fumery
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.